Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 62 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)Active, not recruitingNCT04380636Phase 3
• Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung CancerActive, not recruitingNCT04379739Phase 2
• Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04379635Phase 3
• Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic CancerStatus unknownNCT04377048Phase 2
• Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype MelanomaTerminatedNCT04375527Phase 2
• Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)CompletedNCT04373265Phase 1
• Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin LymphomaWithdrawnNCT04373083Phase 2
• IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMMLCompletedNCT04372433Phase 1
• Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLCStatus unknownNCT04371796Phase 2
• Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.Status unknownNCT04368273Phase 1/2
• Lenvatinib Combined Toripalimab in Advanced Hepatocellular CarcinomaStatus unknownNCT04368078Phase 2
• Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric CancerStatus unknownNCT04367025Phase 2
• First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLCStatus unknownNCT04363255Phase 2
• A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR ExpressionsStatus unknownNCT04363242Phase 1
• Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal CancerCompletedNCT04362839Phase 1
• Study of Dara-Pembro for Multiple Myeloma PatientsWithdrawnNCT04361851Phase 2
• Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer SubjectsCompletedNCT04361825Phase 2
• Nivolumab + Ipilimumab + Radiation in MSS Pancreatic CancerActive, not recruitingNCT04361162Phase 2
• Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant CyclophosphamideWithdrawnNCT04361058Phase 1
• PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast CancerActive, not recruitingNCT04360941Phase 1
• Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant ChemotherapyStatus unknownNCT04359550Phase 3
• Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.CompletedNCT04358237Phase 1/2
• Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different LocationsCompletedNCT04357873Phase 2
• A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid TumorsCompletedNCT04357756Phase 1
• Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal CancerCompletedNCT04357587Phase 1
• The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue SarcomaStatus unknownNCT04356872Phase 2
• A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic MelanomaActive, not recruitingNCT04356729Phase 2
• COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1Status unknownNCT04356508Phase 2
• Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal MetastasisStatus unknownNCT04356222Phase 4
• Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Phase 2
• Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric CancerCompletedNCT04354662Phase 2
• A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant TumorsCompletedNCT04353830Phase 1
• Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid LeukemiaStatus unknownNCT04353479Phase 2
• Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade OsteosarcomaStatus unknownNCT04351308Phase 2
• Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaCompletedNCT04350190Phase 2
• Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid TumorCompletedNCT04346381Phase 2
• Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid TumorsCompletedNCT04344795Phase 1
• A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Phase 3
• Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.Status unknownNCT04343144Phase 2
• Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin LymphomaStatus unknownNCT04342936Phase 3
• PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric AdenocarcinomaStatus unknownNCT04341857Phase 2
• Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 BlockadeActive, not recruitingNCT04340882Phase 2
• Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on NeoantigenStatus unknownNCT04340401Phase 2
• Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCCActive, not recruitingNCT04340258Phase 1/2
• A Phase I Study of CS1002 in Subjects With Advanced Solid TumorsCompletedNCT04338724Phase 1
• A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced CancersCompletedNCT04338659Phase 1
• Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell LymphomaStatus unknownNCT04338282Phase 2
• NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBCActive, not recruitingNCT04335669Phase 3
• Checkpoint Blockade in COVID-19 PandemicTerminatedNCT04335305Phase 2
• First-In-Human Study of EOS884448 in Participants with Advanced Cancers.CompletedNCT04335253Phase 1
• A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.TerminatedNCT04335006Phase 3
• Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant TumorsCompletedNCT04328831Phase 1
• QL1604 Monotherapy for dMMR or MSI-H Advanced Solid TumorsStatus unknownNCT04326829Phase 2
• Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung CancerActive, not recruitingNCT04326153Phase 2
• A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)Status unknownNCT04325763Phase 3
• Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&NCompletedNCT04323202Phase 1
• Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young AdultsActive, not recruitingNCT04323046Phase 1
• CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase InhibitionActive, not recruitingNCT04322955Phase 2
• A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic CarcinomaCompletedNCT04321330Phase 2
• Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib ResistanceStatus unknownNCT04316351Phase 2
• A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin CancerActive, not recruitingNCT04315701Phase 2
• Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof MutationWithdrawnNCT04315155Phase 1
• A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor TypesTerminatedNCT04311710Phase 1
• Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung AdenocarcinomaCompletedNCT04310943Phase 2
• Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular CarcinomaCompletedNCT04310709Phase 2
• Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer PatientsActive, not recruitingNCT04310020Phase 2
• Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung CancerActive, not recruitingNCT04310007Phase 2
• Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk MelanomaActive, not recruitingNCT04309409Phase 3
• A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung CancerTerminatedNCT04308785Phase 2
• A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung CancerStatus unknownNCT04306926Phase 2
• Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological MalignanciesTerminatedNCT04305249Phase 1
• Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)CompletedNCT04305054Phase 1/2
• Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung CancerActive, not recruitingNCT04304248Phase 2
• Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal CancerActive, not recruitingNCT04304209Phase 2
• A Phase II Study of Triple-negative Breast Cancer Brain Metastases.Status unknownNCT04303988Phase 2
• Phase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias With Pembrolizumab (CR-GTP)Status unknownNCT04303884Phase 2
• A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBCStatus unknownNCT04303741Phase 2
• Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLCStatus unknownNCT04303130Phase 2
• PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal CancerActive, not recruitingNCT04301557Phase 2
• Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate CancerCompletedNCT04301414Early Phase 1
• A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457）Status unknownNCT04298320Phase 1/2
• A Study of QL1706 in Subjects With Advanced Malignant TumorStatus unknownNCT04296994Phase 1
• Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II StudyStatus unknownNCT04296786Phase 2
• A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung CancerCompletedNCT04294810Phase 3
• Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric CancerTerminatedNCT04294784Phase 2
• Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of OsteosarcomaStatus unknownNCT04294511Phase 2
• Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus InfectionCompletedNCT04294498Phase 2
• Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal CancerStatus unknownNCT04293419Phase 2
• Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell CarcinomaActive, not recruitingNCT04291885Phase 2
• A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid TumorStatus unknownNCT04291248Phase 2
• Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsActive, not recruitingNCT04291105Phase 2
• Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr CancerActive, not recruitingNCT04289779Phase 2
• Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the TreatmentTerminatedNCT04287894Phase 1
• Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma PatientsActive, not recruitingNCT04287829Phase 2
• A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCCStatus unknownNCT04286958Phase 2
• Dose-escalation Study of APG-1387 and Toripalimab in Solid TumorsTerminatedNCT04284488Phase 1/2
• PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLCStatus unknownNCT04284202Phase 2
• Study of Select Combinations in Adults With MyelofibrosisWithdrawnNCT04283526Phase 1
• Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid TumorStatus unknownNCT04282278Phase 2
• A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCLWithdrawnNCT04279938Phase 1

← Immune Checkpoint Inhibitors overview